PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
加利福尼亚州圣荷西,2024年11月26日(环球新闻)-- PROCEPt 机器人科技(纳斯达克:PRCT)(以下简称"公司"),是一家专注于通过开发变革性泌尿外科手术解决方案来改善患者护理的外科机器人公司,今天宣布管理层成员将在即将举行的第36届派杰投资医疗大会上进行演讲,会议将在纽约市举行。管理层定于12月4日东部时间上午8:30进行演讲。
A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: . The webcasts will be archived and available for replay for at least 90 days after the event.
每场活动的现场网络直播以及档案录音将在公司的官方网站的"投资者"部分提供。网络直播将在活动后至少90天内保存,并可供回放。
About PROCEPT BioRobotics Corporation
关于PROCEPT BioRobotics公司
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
PROCEPt BioRobotics是一家专注于提高泌尿学患者护理水平的外科机器人公司。HYDROS机器人系统是唯一一款采用人工智能技术的机器人技术,可提供水刀消融疗法。PROCEPt BioRobotics设计了水刀消融疗法,可为患有由于BPH引起的下尿路症状或LUTS的男性提供有效、安全和持久的治疗效果,无论前列腺大小和形状,或者外科医生经验如何。BPH是最常见的前列腺疾病,约影响着4,000万美国男性。该公司已经开发了大量临床证据,并有150多项同行评议的出版物,支持水刀消融疗法的益处和临床优势。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投资者联系人:
Matt Bacso
副总裁,投资者关系和业务运营
m.bacso@procept-biorobotics.com